Bot JC, Barkhof F, Polman CH, Lycklama a Nijeholt GJ, de Groot V, Bergers E, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology. 2004;62:226–33.

Article  CAS  PubMed  Google Scholar 

Lukas C, Sombekke MH, Bellenberg B, Hahn HK, Popescu V, Bendfeldt K, et al. Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. Radiology. 2013;269:542–52.

Article  PubMed  Google Scholar 

Brownlee WJ, Altmann DR, Prados F, Miszkiel KA, Eshaghi A, Gandini Wheeler-Kingshott CAM, et al. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain. 2019;142:2276–87.

Article  PubMed  Google Scholar 

Lauerer M, McGinnis J, Bussas M, El Husseini M, Pongratz V, Engl C, et al. Prognostic value of spinal cord lesion measures in early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023. https://doi.org/10.1136/jnnp-2023-331799.

Article  PubMed  Google Scholar 

Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019;15:287–300.

Article  PubMed  Google Scholar 

Li H, Hu F, Zhang Y, Li K. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. J Neurol. 2020;267:3489–98.

Article  PubMed  Google Scholar 

Kreiter D, Spee R, Merry A, Hupperts R, Gerlach O. Effect of disease-modifying treatment on spinal cord lesion formation in multiple sclerosis: a retrospective observational study. Mult Scler Relat Disord. 2023;79: 104994.

Article  CAS  PubMed  Google Scholar 

Henmar S, Simonsen EB, Berg RW. What are the gray and white matter volumes of the human spinal cord? J Neurophysiol. 2020;124:1792–7.

Article  PubMed  Google Scholar 

Thron AK. Vascular anatomy of the spinal cord: radioanatomy as the key to diagnosis and treatment. Berlin: Springer; 2016.

Book  Google Scholar 

Bartanusz V, Jezova D, Alajajian B, Digicaylioglu M. The blood-spinal cord barrier: morphology and clinical implications. Ann Neurol. 2011;70:194–206.

Article  PubMed  Google Scholar 

Pan W, Banks WA, Kastin AJ. Permeability of the blood-brain and blood-spinal cord barriers to interferons. J Neuroimmunol. 1997;76:105–11.

Article  CAS  PubMed  Google Scholar 

Goverman J. Autoimmune t cell responses in the central nervous system. Nat Rev Immunol. 2009;9:393–407.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnson MC, Pierson ER, Spieker AJ, Nielsen AS, Posso S, Kita M, et al. Distinct t cell signatures define subsets of patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3: e278.

Article  PubMed  PubMed Central  Google Scholar 

Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M, et al. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: An expert opinion. J Neurol. 2022;269:5382–94.

Article  PubMed  PubMed Central  Google Scholar 

He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19:307–16.

Article  CAS  PubMed  Google Scholar 

Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. Neurology. 2018;90:e1805–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hauser S, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. B-cell depletion and efficacy outcomes with ofatumumab: subgroup analysis from the pooled phase 3 ASCLEPIOS I and II trials (2356). Neurology. 2020;94(15 Supplement):2356.

Article  Google Scholar 

Comi G, Cook S, Giovannoni G, Rieckmann P, Sorensen PS, Vermersch P, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Multiple Scler Relat Disord. 2019;29:168–74.

Article  Google Scholar 

Roos I, Leray E, Casey R, Horakova D, Havrdova E, Izquierdo G, et al. Effects of high- and low-efficacy therapy in secondary progressive multiple sclerosis. Neurology. 2021;97:e869–80.

Article  CAS  PubMed  Google Scholar 

Stuart EA, King G, Imai K, Ho D. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8):1–28.

Google Scholar 

Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol. 2017;16:271–81.

Article  CAS  PubMed  Google Scholar 

DeLuca GC, Alterman R, Martin JL, Mittal A, Blundell S, Bird S, et al. Casting light on multiple sclerosis heterogeneity: the role of HLA-DRB1 on spinal cord pathology. Brain. 2013;136(Pt 4):1025–34.

Article  PubMed  Google Scholar 

Qiu W, Raven S, James I, Luo Y, Wu J, Castley A, et al. Spinal cord involvement in multiple sclerosis: a correlative MRI and high-resolution HLA-DRB1 genotyping study. J Neurol Sci. 2011;300:114–9.

Article  CAS  PubMed  Google Scholar 

Hampton DW, Anderson J, Pryce G, Irvine KA, Giovannoni G, Fawcett JW, et al. An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J Neuroimmunol. 2008;201–202:200–11.

Article  PubMed  Google Scholar 

Wolswijk G. Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord. Brain. 2002;125(Pt 2):338–49.

Article  PubMed  Google Scholar 

Frischer JM, Weigand SD, Guo Y, Kale N, Parisi JE, Pirko I, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78:710–21.

Article  PubMed  PubMed Central  Google Scholar 

Filippi M, Brück W, Chard D, Fazekas F, Geurts JJG, Enzinger C, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2019;18:198–210.

Article  PubMed  Google Scholar 

Petrova N, Carassiti D, Altmann DR, Baker D, Schmierer K. Axonal loss in the multiple sclerosis spinal cord revisited. Brain Pathol. 2018;28:334–48.

Article  CAS  PubMed  Google Scholar 

DeLuca GC, Ebers GC, Esiri MM. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain. 2004;127(Pt 5):1009–18.

Article  CAS  PubMed  Google Scholar 

Combes AJE, Clarke MA, O’Grady KP, Schilling KG, Smith SA. Advanced spinal cord MRI in multiple sclerosis: current techniques and future directions. NeuroImage Clin. 2022. https://doi.org/10.1016/j.nicl.2022.103244.

Article  PubMed  PubMed Central  Google Scholar 

Rissanen E, Tuisku J, Rokka J, Paavilainen T, Parkkola R, Rinne JO, et al. In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand (1)(1)c-PK11195. J Nucl Med. 2014;55:939–44.

Article  CAS  PubMed  Google Scholar 

Stankiewicz JM, Neema M, Alsop DC, Healy BC, Arora A, Buckle GJ, et al. Spinal cord lesions and clinical status in multiple sclerosis: a 1.5 T and 3 T MRI study. J Neurol Sci. 2009;279:99–105.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wattjes MP, Ciccarelli O, Reich DS, Banwell B, de Stefano N, Enzinger C, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patient